Parsifal Capital Management LP Trims Stock Holdings in The Clorox Company (NYSE:CLX)

Parsifal Capital Management LP decreased its holdings in shares of The Clorox Company (NYSE:CLX - Free Report) by 6.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 651,154 shares of the company's stock after selling 42,634 shares during the quarter. Clorox makes up about 8.8% of Parsifal Capital Management LP's investment portfolio, making the stock its 5th biggest holding. Parsifal Capital Management LP owned 0.53% of Clorox worth $105,754,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Brooklyn Investment Group lifted its stake in Clorox by 163.8% in the fourth quarter. Brooklyn Investment Group now owns 153 shares of the company's stock valued at $25,000 after acquiring an additional 95 shares during the last quarter. Redwood Park Advisors LLC acquired a new stake in Clorox in the fourth quarter valued at $26,000. Millstone Evans Group LLC acquired a new stake in Clorox in the fourth quarter valued at $31,000. Asset Planning Inc acquired a new stake in Clorox in the fourth quarter valued at $32,000. Finally, GKV Capital Management Co. Inc. acquired a new stake in Clorox in the fourth quarter valued at $32,000. Institutional investors and hedge funds own 78.53% of the company's stock.

Clorox Price Performance

CLX stock traded down $1.60 during mid-day trading on Monday, hitting $134.68. The stock had a trading volume of 730,290 shares, compared to its average volume of 1,318,928. The company has a current ratio of 0.94, a quick ratio of 0.60 and a debt-to-equity ratio of 20.52. The Clorox Company has a 52 week low of $127.60 and a 52 week high of $171.37. The firm has a market capitalization of $16.60 billion, a P/E ratio of 36.81, a P/E/G ratio of 2.62 and a beta of 0.60. The firm has a fifty day simple moving average of $141.05 and a 200 day simple moving average of $153.29.

Clorox (NYSE:CLX - Get Free Report) last released its earnings results on Monday, May 5th. The company reported $1.45 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.12). Clorox had a net margin of 6.38% and a return on equity of 316.87%. The firm had revenue of $1.67 billion during the quarter, compared to the consensus estimate of $1.74 billion. During the same period in the prior year, the business earned $1.71 earnings per share. Clorox's quarterly revenue was down 8.0% compared to the same quarter last year. As a group, research analysts forecast that The Clorox Company will post 7.15 EPS for the current year.

Clorox Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, May 9th. Stockholders of record on Wednesday, April 23rd were paid a $1.22 dividend. The ex-dividend date was Wednesday, April 23rd. This represents a $4.88 dividend on an annualized basis and a dividend yield of 3.62%. Clorox's payout ratio is currently 87.61%.

Insiders Place Their Bets

In other news, Director Pierre R. Breber acquired 4,000 shares of Clorox stock in a transaction dated Wednesday, May 7th. The shares were bought at an average cost of $136.57 per share, with a total value of $546,280.00. Following the purchase, the director now owns 4,000 shares in the company, valued at $546,280. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 0.57% of the company's stock.

Wall Street Analyst Weigh In

CLX has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. cut their price target on shares of Clorox from $151.00 to $144.00 and set a "neutral" rating for the company in a research note on Tuesday, May 6th. Citigroup dropped their price objective on shares of Clorox from $165.00 to $150.00 and set a "neutral" rating on the stock in a research report on Monday, April 14th. Morgan Stanley dropped their price objective on shares of Clorox from $165.00 to $150.00 and set an "equal weight" rating on the stock in a research report on Tuesday, May 6th. UBS Group dropped their price objective on shares of Clorox from $176.00 to $154.00 and set a "neutral" rating on the stock in a research report on Thursday, April 17th. Finally, Barclays dropped their price objective on shares of Clorox from $134.00 to $129.00 and set an "underweight" rating on the stock in a research report on Wednesday, May 7th. Three research analysts have rated the stock with a sell rating, eleven have issued a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat.com, Clorox has an average rating of "Hold" and an average target price of $151.23.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.